These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38521180)

  • 1. Developing deep learning-based strategies to predict the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease from electronic health records.
    Li Z; Lan L; Zhou Y; Li R; Chavin KD; Xu H; Li L; Shih DJH; Jim Zheng W
    J Biomed Inform; 2024 Apr; 152():104626. PubMed ID: 38521180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing deep learning-based strategies to predict the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease from electronic health records.
    Li Z; Lan L; Zhou Y; Li R; Chavin KD; Xu H; Li L; Shih DJH; Zheng WJ
    medRxiv; 2023 Nov; ():. PubMed ID: 38014193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease - who and how?
    Teng ML; Tan DJH; Ng CH; Huang DQ
    Clin Mol Hepatol; 2023 Apr; 29(2):404-407. PubMed ID: 36916168
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.
    Ueno M; Takeda H; Takai A; Seno H
    World J Gastroenterol; 2022 Jul; 28(27):3410-3421. PubMed ID: 36158261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.
    Behari J; Gougol A; Wang R; Luu HN; Paragomi P; Yu YC; Molinari M; Chopra K; Malik SM; Geller D; Yuan JM
    Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37395730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis.
    Ioannou GN; Tang W; Beste LA; Tincopa MA; Su GL; Van T; Tapper EB; Singal AG; Zhu J; Waljee AK
    JAMA Netw Open; 2020 Sep; 3(9):e2015626. PubMed ID: 32870314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Kanneganti M; Singal AG
    Gastroenterology; 2022 May; 162(6):1772-1774. PubMed ID: 35120916
    [No Abstract]   [Full Text] [Related]  

  • 9. Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to Hepatocellular Carcinoma Development Without Cirrhosis.
    Phan J; Ng V; Sheinbaum A; French S; Choi G; El Kabany M; Durazo F; Saab S; Tong M; Busuttil R; Han SH
    J Clin Gastroenterol; 2019 Apr; 53(4):309-313. PubMed ID: 29912756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD.
    Kim GA; Park Y; Oh SJ; Jung J; Han S; Chang HS; Park SW; Kim TH; Park HW; Choe J; Kim J; Lee HC
    Liver Int; 2024 Mar; 44(3):738-748. PubMed ID: 38110797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey.
    Cotrim HP; Oliveira CP; Coelho HS; Alvares-da-Silva MR; Nabuco L; Parise ER; Ivantes C; Martinelli AL; Galizzi-Filho J; Carrilho FJ
    Clinics (Sao Paulo); 2016 May; 71(5):281-4. PubMed ID: 27276398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial intelligence model with deep learning in nonalcoholic fatty liver disease diagnosis: genetic based artificial neural networks.
    Ülger Y; Delik A
    Nucleosides Nucleotides Nucleic Acids; 2023; 42(5):398-406. PubMed ID: 36448439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of nonalcoholic fatty liver disease and liver cancer.
    Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
    World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and management issues of NAFLD-related HCC: what we know so far.
    Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A
    Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation.
    Younossi ZM
    Liver Transpl; 2018 Feb; 24(2):166-170. PubMed ID: 29272073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Cernea S; Onișor D
    World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artificial Intelligence in Liver Diseases: Recent Advances.
    Lu F; Meng Y; Song X; Li X; Liu Z; Gu C; Zheng X; Jing Y; Cai W; Pinyopornpanish K; Mancuso A; Romeiro FG; Méndez-Sánchez N; Qi X
    Adv Ther; 2024 Mar; 41(3):967-990. PubMed ID: 38286960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
    Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY
    Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.